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Berberine is an alkaloid with a wide range of reported beneficial health effects. The current work 
provides an extensive literature analysis on berberine. Bibliometric data were identified by means 
of the search string TOPIC=(“berberin*” OR “umbellatine*”), which yielded 5,547 publications 
indexed in the Web of Science Core Collection electronic database. The VOSviewer software 
generated bubble maps to visualize semantic terms with citation results. The ratio of original 
articles to reviews was 13.6:1. The literature has been growing more quickly since the 2010s. Major 
contributing countries were China, the United States, India, Japan, and South Korea. Most of the 
publications appeared in journals specialized in pharmacology pharmacy, biochemistry molecular 
biology, chemistry, and plant science. Some of the frequently mentioned chemicals/chemical classes 
were alkaloid, palmatine, jatrorrhizine, coptisine, isoquinoline, and sanguinarine. The prevalent 
medical conditions under investigation included Alzheimer’s disease, cancer, diabetes, and obesity.
KEY WORDS: alkaloid / Alzheimer’s disease / berberine / citation analysis / bibliometrics /  
                                    diabetes / obesity / Web of Science /VOSviewer
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Berberine (systematically named 5,6-dihydro-9,10-dimethoxybenzo[g]-1,3-
benzodioxolo[5,6-a]quinolizinium chloride) is an isoquinoline alkaloid found in 
many Berberidaceae plant species such as Hydrastis canadensis L., Berberis vulgaris, 
Mahonia aquifolium, Xanthorhiza simplicissima, and Phellodendron amurense 
[Imenshahidi and Hosseinzadeh 2016, Sarraf et al. 2019], known and widely used 
in traditional medicine [Jin et al. 2016] and for nutraceutical uses [Santini et al. 
2017, Daliu et al. 2018, Durazzo et al. 2018]. Many potential health benefits of 
berberine have been reported in the earlier studies [Cicero and Baggioni 2016, Zou 
et al. 2017, Fan et al. 2019, Feng et al. 2019, Liang et al. 2019, Mohammadinejad 
et al. 2019, Rabiei et al. 2019]. For example, the oral intake of berberine may lower 
serum cholesterol levels via a post-transcriptional mechanism that is different from 
the mechanism of statins and red yeast rice, overall recommending it as one of the 
promising nutraceuticals that can be used in statin intolerant patients [Kong et al. 2004, 
Banach et al. 2018]. Berberine is also suitable for treating diabetes and obesity via the 
stimulation of adenosine monophosphate-activated protein kinase (AMPK) activity 
[Lee et al. 2006]. It also has anti-inflammatory effects [Kuo et al. 2004], and is studied 
in the context of cancer counteraction [Mondal et al. 2019]. Human serum albumin 
was identified as a potential drug binding site for berberine [Hu et al. 2009]. At the 
same time, berberine shows synergism with other chemical compounds. For instance, 
together with 5’-methoxyhydnocarpin, it shows a strong antimicrobial activity 
against Staphylococcus aureus [Stermitz et al. 2000]. In case of animals, berberine’s 
anti-inflammatory activity was observed through down regulation of inflammatory 
cytokines in ducks infected by Riemerella anatipestifer, which is affecting the duck 
industry [Fernandez et al. 2017].  It was also noticed enhancement of juvenal health 
status of mice Mus musculus as expressed by the significant reductions of apoptotic 
cells and improvement of antioxidant biomarkers [Dkhil et al. 2017].  Additionally, 
the compound confirmed its effectiveness against ductal and invasive carcinoma 
in rats [Karnam et al. 2017] and also as a co-active agent in treatment of chicken 
coccidiosis [Malik et al. 2016]. It was also found to significantly inhibit the progress 
of oxidative stress, reducing apoptosis and enhancing the immunity when tested as a 
functional feed additive of blunt snout bream fed with high-fat diet [Chen et al. 2016, 
Huminiecki et al. 2017, Tewari et al. 2017ab, Tewari et al. 2018, Huminiecki and 
Horbańczuk 2018, Mozos et al. 2018, Wang et al. 2018]. All the above-mentioned 
examples illustrate the versatility of berberine in bringing health benefits, and hence, 
the growing literature that investigates its effects.
With many publications on the topic of berberine, a systematic bibliometric analysis 
can provide a summary of the research literature, so that readers and researchers can 
quickly grasp the essence and know the directions. Bibliometric analysis is a versatile 
approach, which can be used in different ways to yield diverse information ranging 
from, e.g., characterization of the overall landscape of a given research field [Yeung et 
al. 2019c], through examining effectiveness of manuscript features such as graphical 
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9abstracts on visibility and citations [Pferschy-Wenzig et al. 2016], to the analysis of the 
most cited manuscripts in a specified research area [Yeung et al. 2019d]. The current 
report is aimed at evaluating research publications on berberine from a bibliometric 
perspective. The detailed objectives of the present work are to (1) identify the major 
contributing institutions, countries/regions, and journals; (2) reveal the major research 
themes; (3) unveil the potential health benefits of berberine to animals and humans 
reported by the studies; and (4) report the chemicals/chemical classes that were 
frequently under investigation in the berberine-linked research literature.
Material and methods
In June 2019, a literature search was performed via the Web of Science 
(WoS) electronic platform (Clarivate Analytics, Philadelphia, PA, USA), with its 
Core Collection database chosen as the source of bibliometric data. The authors’ 
subscription to the database allowed a search of papers published since 1956. 
Publications containing the word “berberine” or its derivatives in the title, abstract, or 
keywords were identified using the following search string: TOPIC=(“berberin*” OR 
“umbellatine*”). We did not place additional filters to the search.
Data extraction
The publications resulting from the search have been evaluated for the following 
criteria: (i) publication year, (ii) institution, (iii) country/region of the institution, (iv) 
journal title, (v) WoS category, (vi) publication type, (vii) language, and (viii) citation 
count. The “Analyze” function of the WoS platform identified the most productive 
entities in terms of institution, country/region, journal, and WoS category. The 
VOSviewer software further extracted and analyzed the full records and cited references, 
which enables users to relate the publication and citation data to the words in the titles, 
abstracts, and keywords of the analyzed publications [van Eck and Waltman 2009]. A 
bubble map with default parameters visualizes the outcome of our work. The bubble 
size, proximity, and color correspond to the frequency of appearance, co-appearance, 
as well as averaged citations respectively. Multiple mentioning of a particular word in 
a publication was counted as a single appearance. Words that appeared in at least 1.0% 
(n = 56) of the publications have been analyzed and visualized.
Results and discussion
The literature search resulted in 5,547 publications to be analyzed, with a total 
number of citations of 111,999 by 54,127 citing publications, which meant that each 
publication received 20.2 citations per publication (CPP) on average. The earliest 
berberine publications indexed in WoS were published in 1970, and these investigated 
the effects of berberine on the central nervous [Shanbhag et al. 1970] and cardiovascular 
systems [Fukuda et al. 1970]. The literature on the topic accrued more quickly in the 
Berberine research literature analysis
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Fig. 1. Cumulative annual publication count of berberine publications.
 Table 1. Top five contributing institutions, countries/regions, journals, and Web of Science categories of the berberine publications 
 
Contributor  
Publication 
count  
(% of total) 
 Citation per publication 
Institution     
Council of Scientific and Industrial Research (India)  193 (3.5)  25.0 
Chinese Academy of Sciences  177 (3.2)  22.2 
Indian Institute of Chemical Biology  131 (2.4)  29.6 
China Pharmaceutical University  124 (2.2)  15.8 
Chinese Academy of Medical Sciences Peking Union Medical College  114 (2.1)  24.5 
     
Country / Territory     
China  2,431 (43.8)  16.7 
United States  645 (11.6)  31.9 
India  483 (8.7)  19.3 
Japan  408 (7.4)  27.1 
South Korea  348 (6.3)  21.9 
     
Journal     
PLOS One  95 (1.7)  26.3 
Journal of Ethnopharmacology  84 (1.5)  33.4 
Evidence-based Complementary and Alternative Medicine  75 (1.4)    7.9 
Planta Medica  68 (1.2)  25.6 
European Journal of Pharmacology  65 (1.2)  31.2 
     
WoS category     
Pharmacology pharmacy  1,408 (25.4)  21.8 
Biochemistry molecular biology  761 (13.7)  26.8 
Chemistry medicinal  715 (12.9)  23.5 
Chemistry analytical  571 (10.3)  16.1 
Plant sciences  514 (9.3)  30.7 
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2010s as compared to the 1990s and 2000s (Fig. 1). The ratio of original articles (n = 
4,735) to reviews (n = 348) was 13.6:1, which was much higher than the literature on 
curcumin (10.4:1) [Yeung et al. 2019b], resveratrol (9.5:1) [Yeung et al. 2019a], or 
dietary natural products (1.5:1) [Yeung et al. 2018]. English was the mainstream written 
language of the berberine publications (n = 5,378, 97.0%). The publications were 
contributed by over 3,400 institutions located in 101 countries/regions and published in 
over 1,400 journals. The top five contributors with regard to institution, country/region, 
journal, and WoS category are listed in Table 1. The most productive institutions were 
all based in China and India, the 1st and 3rd most productive countries, respectively. 
China contributed to nearly half of the berberine publications (43.8%). Most of these 
publications did not involve international collaborations (2,089/2,431, 85.9%). PLOS 
One was the most productive journal, and many publications were published in journals 
dealing with pharmacology pharmacy, biochemistry molecular biology, and chemistry.
Around 420 terms appeared in at least 1.0% (n = 56) of the analyzed publications’ 
titles and abstracts (Fig. 2). Some major themes were related to treatment (n = 1,339, 
CPP = 22.3), mechanism (n = 1,092, CPP = 24.1), expression (n = 974, CPP = 24.1), and 
pathway (n = 797, CPP = 24.1). There were red bubbles of terms concerning diabetes 
and obesity at the lower left of the map, and terms concerning DNA-binding at the 
upper right. Some frequently mentioned chemicals/chemical classes were alkaloid (n 
= 878, CPP = 23.4), palmatine (n = 513, CPP = 21.8), jatrorrhizine (n = 261, CPP 
= 18.2), coptisine (n = 257, CPP = 17.8), isoquinoline (n = 257, CPP = 23.0), and 
sanguinarine (n = 152, CPP = 34.7) (Fig. 3). Interestingly, all these structures are closely 
related, strongly suggesting their implication in berberine structure-function research 
and discussion.
Berberine research literature analysis
 
Fig. 2. Bubble map visualizing words from titles and abstracts of the 5,547 berberine publications. There 
were 420 terms that appeared in at least 1.0% (n = 56) of the publications’ titles and abstracts and hence 
visualized. The bubble size, proximity, and color indicate the frequency of appearance, co-appearance, 
and averaged citations respectively.
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Fig. 4. Bubble map visualizing keywords of the 5,547 berberine publications. There were 105 keywords 
(author keywords and Web of Science KeyWords Plus) that appeared in at least 1.0% (n = 56) of the 
publications and hence visualized. The bubble size, proximity, and color indicate the frequency of 
appearance, co-appearance, and averaged citations respectively.
There were 105 keywords appeared in at least 1.0% of the publications (Fig. 4). 
The keyword in vitro (n = 540, CPP = 22.3) was listed more frequently than in vivo 
(n = 85, CPP = 22.5), and the animal models were usually rats (n = 256, CPP = 19.4), 
and mice (n = 216, CPP = 20.5). Medical conditions under investigation included 
Fig. 3. Chemical structures of key single chemicals or chemical classes associated with them that were 
often discussed in the analyzed berberine-related publications.
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Alzheimer’s disease (AD) (n = 78, CPP = 16.9), cancer (n = 125, CPP = 26.5), diabetes 
(n = 70, CPP = 27.0), and obesity (n = 94, CPP = 17.4). The 20 commonest keywords 
are listed in Table 2. Some of the commonest themes were apoptosis, oxidative stress, 
inflammation, and pharmacokinetics. 
In vivo studies provided much of evidence on the potential beneficial effects of 
berberine on animal health. For instance, intraperitoneal injection of berberine was 
shown to reduce body weight and improve glucose tolerance in mice, whereas its 
oral administration could similarly reduce body weight and plasma triglycerides, and 
improve insulin action in rats [Lee et al. 2006, Zhang et al. 2009]. Oral administration 
of berberine also reduced blood cholesterol level in hamsters [Dong et al. 2010].
It was investigated that the antioxidant and anti-inflammatory effects of berberine 
in diabetic animals can be attributed to its modulatory effects on numerous pathways, 
involving adenosine monophosphate-activated protein kinase (AMPK), mitogen-
activated protein kinases (MAPKs), nuclear factor erythroid 2-related factor 2 (Nrf2), 
and nuclear factor kappa B (NF-κB) [Li et al. 2014]. Also, the berberine-related 
prevention of weight gain in rats by berberine was associated with the changes in the 
expression of genes that control energy expenditure [Hu et al. 2014]. Besides diabetes 
and obesity, rats and mice studies also presented promising results that showed the 
nephroprotective [Domitrović et al. 2013], hepatoprotective [Janbaz and Gilani 2000], 
antidepressant [Kulkarni and Dhir 2007], and anti-cancer effects [Anis et al. 2001] of 
berberine.
 Table 2. Top 20 keywords listed by berberine publications  
Keyword  Publication count  
Citation per 
publication 
In vitro  540  22.3 
Expression  534  24.2 
Apoptosis  515  21.1 
Alkaloids  448  18.9 
Cells  346  21.3 
Inhibition  341  28.6 
Oxidative stress  276  19.9 
Activation  269  17.6 
Mechanism  258  23.5 
Rats  256  19.4 
Palmatine  224  19.3 
Mice  216  20.5 
Binding  192  23.3 
Inflammation  191  19.2 
Activated protein kinase  186  26.7 
Growth  184  16.6 
Pathway  178  18.8 
DNA  173  23.7 
Protoberberine alkaloids  172  24.5 
Pharmacokinetics  157  17.9 
 
The word “berberine”, being the most common keyword, 
was excluded from the list. 
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Besides, berberine was also shown to improve endothelial function and arterial 
stiffness in healthy subjects and hypertensive rats [Zhang et al. 2019]. The vascular 
benefits of berberine were related to direct vasorelaxation and suppression of transient 
receptor potential vanilloid 4 channel [Wang et al. 2015]. Considering the effects on 
cardiovascular risk factors and arterial stiffness, further studies are needed to evaluate 
the cardiovascular benefits of berberine.
Regarding cancer, in vitro studies have shown that the inhibitory effects of 
berberine on NF-κB signaling potentiate apoptosis of cancer cells [Pandey et al. 2008, 
Muralimanoharan et al. 2009, Gupta et al. 2010]. In addition, anti-cancer effects of 
berberine are mediated by induction of autophagic cell death through alternating 
AMPK/mTOR signaling or GRP78 levels in different cancer cells [Yu et al. 2014, La 
et al. 2017, Moosavi et al. 2018].
A number of meta-analyses were published to evaluate the efficacy of berberine 
in improving human health. For example, a meta-analysis reported no significant 
difference between berberine and metformin on improving insulin resistance, glycolipid 
metabolism, or reproductive endocrine condition, whereas the combination of the two 
did not outperform metformin [Li et al. 2018]. Meanwhile, berberine significantly 
reduced the levels of total cholesterol, low-density lipoprotein cholesterol, and 
triglycerides, and increased the level of high-density lipoprotein cholesterol, without 
severe adverse effects [Dong et al. 2013, Ju et al. 2018]. In a meta-analyses of type-2 
diabetic patients, berberine was shown to have better antidyslipidemic effect than other 
oral hypoglycaemics, while the combination of berberine with oral hypoglycaemics 
resulted in a better glycaemic control [Dong et al. 2012, Lan et al. 2015]. In the same 
line, Koppen et al. [2017], by summarizing clinical trials of studies using berberine for 
the treatment of hyperlipidemia and other dyslipidemias, concluded that berberine 
could serve as an alternative for patients who are intolerant to statins, patients resistant 
to starting statin therapy but who are open to alternative treatments, and for low-
risk patients not indicated for statin therapy [Koppen et al. 2017]. Furthermore, 
berberine could significantly reduce the fasting plasma glucose, postprandial plasma 
glucose, and glycated hemoglobin levels relative to controls, though such effects 
became insignificant if the treatment lasted more than 90 days and for patients aged 
over 60 years [Liang et al. 2019]. Berberine also enhances cell survival and reduces 
cardiac ischemia/reperfusion injury. The beneficial effect of berberine is mediated 
by inhibiting excessive autophagy in both in vitro and in vivo models [Huang et al. 
2015]. Recently, Xu et al. [2019] carried out systematic review and meta-analysis 
on anticancer effect of berberine based on experimental animal models of various 
cancers; the authors concluded that berberine exerted anti-tumor effects in a variety 
of tumors in vivo, especially breast cancer and lung cancer, whereas the evidences are 
insufficient for colorectal cancer and gastric cancer [Xu et al. 2019]. Readers should 
notice that the conclusions of these meta-analyses often urged for more randomized 
control trials to be conducted in the future due to the small sample size, small number 
of trials, questionable methodological quality, and unidentified risks of bias. There 
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was no meta-analysis on the compound’s impact on other medical conditions, such as 
AD and cancer.
Conclusions
The publications on berberine were – apart from the United States – predominantly 
contributed by Asian countries, such as China, India, Japan, and South Korea. Many 
of the publications focused on the areas of pharmacology pharmacy, biochemistry 
molecular biology, chemistry, and plant science. Frequently mentioned chemicals/
chemical classes were alkaloid, palmatine, jatrorrhizine, coptisine, isoquinoline, and 
sanguinarine. Medical conditions under investigation included AD, cancer, diabetes, 
and obesity. The relevant literature underlines that berberine has multiple potential 
health benefits to both animals and humans. This bibliometric review gives a brief 
total-scale overview of the existing berberine literature and can open new horizons for 
designing further studies examining its bioeffects.
Conflict of interest: The authors declare no conflict of interest.
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